BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesNew…
GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma,…
-Partnership Expands TOMI’s Market in Food, Agriculture, and Cannabis Industries -FREDERICK, Md., Nov. 27, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental…
Resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical…
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today…
Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate…
Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week…
Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50,…
—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive…
Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and…